|
|
| Further to the FTSE notice released on 09 January 2024 in relation to Dechra Pharmaceuticals (UK): Constituent Deletion, please note the replacement in the fixed indices.
All other details remain unchanged. Please see updated notice below:
|
Dechra Pharmaceuticals (UK): Constituent Deletion - Update
Changes in FTSE UK Index Series
11 January 2024
| Subject to court sanctioning the scheme of arrangement in relation to the cash offer for Dechra Pharmaceuticals (UK, constituent) by Freya Bidco Limited (non-constituent), please see details of affected indexes and effective dates below:
|
| Dechra Pharmaceuticals (UK, 0963318) will be deleted from the index.
Persimmon PLC (UK, 0682538) will be added to the FTSE 100 Index and deleted from the FTSE 250 Index.
Baillie Gifford US Growth Trust (UK, BDFGHW4) will be added to the FTSE 250 Index and deleted from the FTSE SmallCap Index.
All changes effective from 16 January 2024
Full details of index changes are available on the FTSE Russell website.
|
|
|
| For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:
Alternatively please visit our website at lseg.com/ftse-russell
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.